These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 39215494)

  • 1. Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab.
    Gibson AW; Elser H; Rosso M; Cornblath EJ; Fonkeu Y; Prasad S; Rothstein A; Nasrallah IM; Wolk DA; Guo MH
    Alzheimers Dement; 2024 Nov; 20(11):8192-8197. PubMed ID: 39215494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
    Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
    Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.
    Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E
    J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications.
    Doran SJ; Sawyer RP
    Front Neurosci; 2024; 18():1326784. PubMed ID: 38312931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lecanemab: Appropriate Use Recommendations.
    Cummings J; Apostolova L; Rabinovici GD; Atri A; Aisen P; Greenberg S; Hendrix S; Selkoe D; Weiner M; Petersen RC; Salloway S
    J Prev Alzheimers Dis; 2023; 10(3):362-377. PubMed ID: 37357276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report.
    Sotoudeh H; Alizadeh M; Shahidi R; Shobeiri P; Love N; Singhal A
    Radiol Case Rep; 2023 Jan; 18(1):275-279. PubMed ID: 36388611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.
    Martens RM; Bechten A; Ingala S; van Schijndel RA; Machado VB; de Jong MC; Sanchez E; Purcell D; Arrighi MH; Brashear RH; Wattjes MP; Barkhof F
    Eur Radiol; 2018 Mar; 28(3):1215-1226. PubMed ID: 28956123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.
    Withington CG; Turner RS
    Front Neurol; 2022; 13():862369. PubMed ID: 35401412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease.
    Yoon CH; Groff C; Criss O
    Innov Pharm; 2024; 15(1):. PubMed ID: 38779110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
    Wang D; Kowalewski EK; Koch G
    Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
    Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
    J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.
    Honig LS; Barakos J; Dhadda S; Kanekiyo M; Reyderman L; Irizarry M; Kramer LD; Swanson CJ; Sabbagh M
    Alzheimers Dement (N Y); 2023; 9(1):e12377. PubMed ID: 36949897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of Amyloid-Related Imaging Abnormalities (ARIA).
    Urbach H; Linn J; Hattingen E; Fiebach J
    Rofo; 2024 Apr; 196(4):363-369. PubMed ID: 37995736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer's Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring.
    Jeong SY; Suh CH; Kim SJ; Lemere CA; Lim JS; Lee JH
    Korean J Radiol; 2024 Aug; 25(8):726-741. PubMed ID: 39109501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis and Treatment of Amyloid-related Imaging Abnormalities Caused by Disease-modifying Drugs in Alzheimer's Disease].
    Tomimoto H
    Brain Nerve; 2024 Sep; 76(9):1011-1017. PubMed ID: 39251220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-Related Imaging Abnormalities: An Update.
    Roytman M; Mashriqi F; Al-Tawil K; Schulz PE; Zaharchuk G; Benzinger TLS; Franceschi AM
    AJR Am J Roentgenol; 2023 Apr; 220(4):562-574. PubMed ID: 36321981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
    Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of lecanemab for the treatment of Alzheimer's disease: A systematic review.
    Hossain MF; Husna AU; Kharel M
    Brain Behav; 2024 Jun; 14(6):e3592. PubMed ID: 38867460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.